Mesenchymal Stem Cells And Uses Therefor

• US 20090180997A1
• Filed: 11/25/2008
• Published: 07/16/2009
• Est. Priority Date: 03/22/2004
• Status: Abandoned Application

• Current Assignee: Mesoblast International Srl
• Original Assignee: Mesoblast International Srl
• Inventors: Aggarwal, Sudeepta, Pittenger, Mark F.
• Application Number:
  US12/323,129
• Publication Number:
  US 20090180997A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/2026 IL-4
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 : of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 5/0662 : Stem cells
• CPC Class Codes: C12N 5/0663 : Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0664 : Dental pulp stem cells, Dental follicle stem cells
• CPC Class Codes: C12N 5/0665 : Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: C12N 5/0666 : Mesenchymal stem cells from hair follicles
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, and promoting anglogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

Claims

1-28. -28. (canceled)

29. A method of controlling inflammation in an eye of an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to control said inflammation.

30. The method of claim 29, wherein said inflammation is in a cornea, lens, pigment epithelium, or retina.

31. The method of claim 29, wherein said inflammation is associated with uveitis.

32. The method of claim 29, wherein said mesenchymal stem cells are allogeneic mesenchymal stem cells.

33. The method of claim 29, wherein said mesenchymal stem cells are CD73⁺.

34. The method of claim 29, wherein said mesenchymal stem cells are CD105⁺.

35. The method of claim 29, wherein said mesenchymal stem cells are allogeneic CD73⁺/CD105⁺ mesenchymal stem cells.

36. The method of claim 29, wherein said mesenchymal stem cells are administered intravenously.

37. A method of treating an inflammatory response in an eye of an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat said inflammatory response.

38. The method of claim 37, wherein said inflammatory response is in a cornea, lens, pigment epithelium, or retina.

39. The method of claim 37, wherein said inflammatory response is associated with uveitis.

40. The method of claim 37, wherein said mesenchymal stem cells are allogeneic mesenchymal stem cells.

41. The method of claim 37, wherein said mesenchymal stem cells are CD73⁺.

42. The method of claim 37, wherein said mesenchymal stem cells are CD105⁺.

43. The method of claim 37, wherein said mesenchymal stem cells are allogeneic CD73⁺/CD105⁺ mesenchymal stem cells.

44. The method of claim 37, wherein said mesenchymal stem cells are administered intravenously.

45. A method of treating autoimmune uveitis in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat said uveitis.

46. The method of claim 45, wherein said mesenchymal stem cells are allogeneic mesenchymal stem cells.

47. The method of claim 45, wherein said mesenchymal stem cells are CD73⁺.

48. The method of claim 45, wherein said mesenchymal stem cells are CD105⁺.

49. The method of claim 45, wherein said mesenchymal stem cells are allogeneic CD73⁺/CD105⁺ mesenchymal stem cells.

50. The method of claim 45, wherein said mesenchymal stem cells are administered intravenously.